1.Kernéis S, Boëlle PY, Grais RF, Pavillon G, Jougla E, Flahault A, et al. Mortality trends in systemic sclerosis in France and USA, 1980-1998: an age-period-cohort analysis. Eur J Epidemiol. 2010;25(1):55–61.
1.Ziadé N, Jougla E, Coste J. Population-level impact of osteoporotic fractures on mortality and trends over time: a nationwide analysis of vital statistics for France, 1968-2004. Am J Epidemiol. 2010 Oct 15;172(8):942–51.
Goldberg S, Rey G, Luce D, Gilg Soit Ilg A, Rolland P, Brochard P, et al. Possible effect of environmental exposure to asbestos on geographical variation in mesothelioma rates. Occup Environ Med. 2010 Jun;67(6):417–21.
1.Tukenova M, Guibout C, Oberlin O, Doyon F, Mousannif A, Haddy N, et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol. 2010 Mar 10;28(8):1308–15.
Launay E, Gras-Le Guen C, Martinot A, Assathiany R, Blanchais T, Mourdi N, et al. Suboptimal care in the initial management of children who died from severe bacterial infection: a population-based confidential inquiry. Pediatr Crit Care Med. 2010 Jul;11(4):469–74.
Béjot Y, Aouba A, de Peretti C, Grimaud O, Aboa-Eboulé C, Chin F, et al. Time trends in hospital-referred stroke and transient ischemic attack: results of a 7-year nationwide survey in France. Cerebrovasc Dis. 2010;30(4):346–54.
Nelson DE, Jarman DW, Rehm J, Greenfield TK, Rey G, Kerr WC, et al. Alcohol-attributable cancer deaths and years of potential life lost in the United States. Am J Public Health. 2013 Apr;103(4):641–8.
1.Hoffmann R, Plug I, Khoshaba B, McKee M, Mackenbach JP, AMIEHS working group. Amenable mortality revisited: the AMIEHS study. Gac Sanit. 2013 Jun;27(3):199–206.
1.Menvielle G, Rey G, Jougla E, Luce D. Diverging trends in educational inequalities in cancer mortality between men and women in the 2000s in France. BMC Public Health. 2013 Sep 10;13(1):823.
1.Hoffmann R, Plug I, McKee M, Khoshaba B, Westerling R, Looman C, et al. Innovations in health care and mortality trends from five cancers in seven European countries between 1970 and 2005. Int J Public Health. 2013 Aug 29;
1.Hoffmann R, Plug I, McKee M, Khoshaba B, Westerling R, Looman C, et al. Innovations in medical care and mortality trends from four circulatory diseases between 1970 and 2005. Eur J Public Health. 2013 Oct;23(5):852–7.
Marijon E, Tafflet M, Antero-Jacquemin J, El Helou N, Berthelot G, Celermajer DS, et al. Mortality of French participants in the Tour de France (1947-2012). Eur Heart J. 2013 Oct;34(40):3145–50.
Rafnsson SB, Bhopal RS, Agyemang C, Fagot-Campagna A, Harding S, Hammar N, et al. Sizable variations in circulatory disease mortality by region and country of birth in six European countries. Eur J Public Health. 2013 Aug;23(4):594–605.
Ghosn W, Kassie D, Jougla E, Rican S, Rey G. Spatial interactions between urban areas and cause-specific mortality differentials in France. Health Place. 2013 Nov;24:234–41.
Ghosn W, Kassié D, Jougla E, Salem G, Rey G, Rican S. Trends in geographic mortality inequalities and their association with population changes in France, 1975-2006. Eur J Public Health. 2013 Oct;23(5):834–40.
Mackenbach JP, Hoffmann R, Khoshaba B, Plug I, Rey G, Westerling R, et al. Using “amenable mortality” as indicator of healthcare effectiveness in international comparisons: results of a validation study. J Epidemiol Community Health. 2013 Feb;67(2):139–46.
1.Rey G, Jougla E. Are alcohol-attributable mortality estimates reliable? Eur J Public Health. 2014 Feb;24(1):3–4.
1.Lamarche-Vadel A, Pavillon G, Aouba A, Johansson LA, Meyer L, Jougla E, et al. Automated comparison of last hospital main diagnosis and underlying cause of death ICD10 codes, France, 2008-2009. BMC Med Inform Decis Mak. 2014;14:44.
1.Morlat P, Roussillon C, Henard S, Salmon D, Bonnet F, Cacoub P, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS. 2014 May 15;28(8):1181–91.
1.Viallon V, Banerjee O, Jougla E, Rey G, Coste J. Empirical comparison study of approximate methods for structure selection in binary graphical models. Biom J. 2014 Mar;56(2):307–31.
1.Vuillermoz C, Aouba A, Grout L, Vandentorren S, Tassin F, Vazifeh L, et al. Estimating the number of homeless deaths in France, 2008-2010. BMC Public Health. 2014;14:690.
Saucedo M, Bouvier-Colle MH, Chantry AA, Lamarche-Vadel A, Rey G, Deneux-Tharaux C. Pitfalls of national routine death statistics for maternal mortality study. Paediatr Perinat Epidemiol. 2014 Nov;28(6):479–88.
Lefeuvre D, Pavillon G, Aouba A, Lamarche-Vadel A, Fouillet A, Jougla E, et al. Quality comparison of electronic versus paper death certificates in France, 2010. Popul Health Metr. 2014;12(1):3.
Romon I, Rey G, Mandereau-Bruno L, Weill A, Jougla E, Eschwège E, et al. The excess mortality related to cardiovascular diseases and cancer among adults pharmacologically treated for diabetes--the 2001-2006 ENTRED cohort. Diabet Med. 2014 Aug;31(8):946–53.
1.Westerling R, Westin M, McKee M, Hoffmann R, Plug I, Rey G, et al. The timing of introduction of pharmaceutical innovations in seven European countries. J Eval Clin Pract. 2014 Aug;20(4):301–10.
1.Clergue F, Auroy Y, Pequignot F, Jougla E, Lienhart A, Laxenaire MC. Evolution of the anaesthetic workload--the French experience. Best Pract Res Clin Anaesthesiol. 2002 Sep;16(3):459–73.
Rey G, Bounebache K, Rondet C. Causes of deaths data, linkages and big data perspectives. J Forensic Leg Med. 2018 Jul;57:37–40.
Chazal T, Lhote R, Rey G, Haroche J, Eb M, Amoura Z, et al. Giant-cell arteritis-related mortality in France: A multiple-cause-of-death analysis. Autoimmun Rev. 2018 Dec;17(12):1219–24.
Aouba A, Gonzalez Chiappe S, Eb M, Delmas C, de Boysson H, Bienvenu B, et al. Mortality causes and trends associated with giant cell arteritis: analysis of the French national death certificate database (1980-2011). Rheumatology (Oxford). 2018 Jun 1;57(6):1047–55.
Chaignot C, Zureik M, Rey G, Dray-Spira R, Coste J, Weill A. Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France. Pharmacoepidemiol Drug Saf. 2018 Nov;27(11):1239–48.